LLY
Price
$843.63
Change
-$1.42 (-0.17%)
Updated
Oct 7 closing price
Capitalization
756.28B
22 days until earnings call
PFE
Price
$26.19
Change
-$0.08 (-0.30%)
Updated
Oct 8, 11:27 AM (EDT)
Capitalization
149.36B
27 days until earnings call
Interact to see
Advertisement

LLY vs PFE

Header iconLLY vs PFE Comparison
Open Charts LLY vs PFEBanner chart's image
Eli Lilly & Co
Price$843.63
Change-$1.42 (-0.17%)
Volume$2.61M
Capitalization756.28B
Pfizer
Price$26.19
Change-$0.08 (-0.30%)
Volume$32.34K
Capitalization149.36B
LLY vs PFE Comparison Chart in %
View a ticker or compare two or three
VS
LLY vs. PFE commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a StrongBuy and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (LLY: $843.63 vs. PFE: $26.27)
Brand notoriety: LLY and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: LLY: 51% vs. PFE: 92%
Market capitalization -- LLY: $756.28B vs. PFE: $149.36B
LLY [@Pharmaceuticals: Major] is valued at $756.28B. PFE’s [@Pharmaceuticals: Major] market capitalization is $149.36B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $756.28B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $96.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LLY’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • LLY’s FA Score: 2 green, 3 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, LLY is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LLY’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).

  • LLY’s TA Score: 6 bullish, 4 bearish.
  • PFE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, LLY is a better buy in the short-term than PFE.

Price Growth

LLY (@Pharmaceuticals: Major) experienced а +10.57% price change this week, while PFE (@Pharmaceuticals: Major) price change was +3.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.26%. For the same industry, the average monthly price growth was +1.81%, and the average quarterly price growth was +24.56%.

Reported Earning Dates

LLY is expected to report earnings on Oct 30, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.26% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LLY($756B) has a higher market cap than PFE($149B). LLY has higher P/E ratio than PFE: LLY (55.14) vs PFE (13.90). LLY YTD gains are higher at: 9.932 vs. PFE (4.347). PFE (20.2B) and LLY (19.7B) have comparable annual earnings (EBITDA) . PFE has more cash in the bank: 13.2B vs. LLY (3.55B). LLY has less debt than PFE: LLY (39.9B) vs PFE (60.9B). PFE has higher revenues than LLY: PFE (63.8B) vs LLY (53.3B).
LLYPFELLY / PFE
Capitalization756B149B507%
EBITDA19.7B20.2B98%
Gain YTD9.9324.347228%
P/E Ratio55.1413.90397%
Revenue53.3B63.8B84%
Total Cash3.55B13.2B27%
Total Debt39.9B60.9B66%
FUNDAMENTALS RATINGS
LLY vs PFE: Fundamental Ratings
LLY
PFE
OUTLOOK RATING
1..100
7914
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
20100
SMR RATING
1..100
1462
PRICE GROWTH RATING
1..100
4850
P/E GROWTH RATING
1..100
9598
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (10) in the Pharmaceuticals Major industry is significantly better than the same rating for LLY (79). This means that PFE’s stock grew significantly faster than LLY’s over the last 12 months.

LLY's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.

LLY's SMR Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (62). This means that LLY’s stock grew somewhat faster than PFE’s over the last 12 months.

LLY's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as PFE (50). This means that LLY’s stock grew similarly to PFE’s over the last 12 months.

LLY's P/E Growth Rating (95) in the Pharmaceuticals Major industry is in the same range as PFE (98). This means that LLY’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LLYPFE
RSI
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
46%
Bearish Trend 1 day ago
55%
Momentum
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
51%
MACD
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
52%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
52%
Advances
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 8 days ago
57%
Declines
ODDS (%)
Bearish Trend 14 days ago
52%
Bearish Trend 1 day ago
60%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
45%
Bearish Trend 1 day ago
55%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
57%
View a ticker or compare two or three
Interact to see
Advertisement
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AVL54.290.22
+0.41%
Direxion Daily AVGO Bull 2X Shares
VHT268.560.09
+0.03%
Vanguard Health Care ETF
SCDL38.38N/A
N/A
ETRACS 2x Leveraged US Div Fctr TR ETN
MSTB39.97-0.12
-0.30%
LHA Market State Tactical Beta ETF
KSA40.59-0.18
-0.44%
iShares MSCI Saudi Arabia ETF